BRPI0716749B8 - compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende - Google Patents

compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende

Info

Publication number
BRPI0716749B8
BRPI0716749B8 BRPI0716749A BRPI0716749A BRPI0716749B8 BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8 BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 A BRPI0716749 A BR PI0716749A BR PI0716749 B8 BRPI0716749 B8 BR PI0716749B8
Authority
BR
Brazil
Prior art keywords
inhibitors
pyrido
pharmaceutical composition
pyrimidinone compounds
compounds
Prior art date
Application number
BRPI0716749A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhumralkar Dilip
Cheng Hengmiao
Elizabeth Hoffman Jacqui
Tuan Tran Khanh
Ruprecht Dress Klaus
Catherine Johnson Mary
Alan Pairish Mason
Bruno Plewe Michael
David Nambu Mitchell
Thi Quy Le Phuong
Steven Kania Robert
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0716749A2 publication Critical patent/BRPI0716749A2/pt
Publication of BRPI0716749B1 publication Critical patent/BRPI0716749B1/pt
Publication of BRPI0716749B8 publication Critical patent/BRPI0716749B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
BRPI0716749A 2006-09-15 2007-09-03 compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende BRPI0716749B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US60/845,065 2006-09-15
US94785207P 2007-07-03 2007-07-03
US60/947,852 2007-07-03
US95262807P 2007-07-30 2007-07-30
US60/952,628 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0716749A2 BRPI0716749A2 (pt) 2014-02-18
BRPI0716749B1 BRPI0716749B1 (pt) 2020-10-06
BRPI0716749B8 true BRPI0716749B8 (pt) 2021-05-25

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716749A BRPI0716749B8 (pt) 2006-09-15 2007-09-03 compostos pirido (2,3-d) pirimidinona, seu uso como inibidores pi3 e composição farmacêutica que os compreende

Country Status (41)

Country Link
US (3) US7696213B2 (enExample)
EP (1) EP2074122B9 (enExample)
JP (1) JP4718637B2 (enExample)
KR (1) KR101099926B1 (enExample)
CN (1) CN101573358B (enExample)
AP (1) AP2710A (enExample)
AR (1) AR062785A1 (enExample)
AT (1) ATE514695T1 (enExample)
AU (1) AU2007297212B8 (enExample)
BR (1) BRPI0716749B8 (enExample)
CA (1) CA2663401C (enExample)
CL (1) CL2007002682A1 (enExample)
CR (1) CR10662A (enExample)
CU (1) CU23783B7 (enExample)
CY (1) CY1111911T1 (enExample)
DK (1) DK2074122T5 (enExample)
DO (1) DOP2009000039A (enExample)
EA (1) EA016388B1 (enExample)
ES (1) ES2366489T3 (enExample)
GE (1) GEP20115306B (enExample)
GT (1) GT200700077A (enExample)
HN (1) HN2007000267A (enExample)
HR (1) HRP20110621T2 (enExample)
IL (1) IL197243A (enExample)
MA (1) MA30709B1 (enExample)
ME (1) MEP8009A (enExample)
MX (1) MX2009002927A (enExample)
MY (1) MY146420A (enExample)
NI (1) NI200900032A (enExample)
NO (1) NO342357B1 (enExample)
NZ (1) NZ575167A (enExample)
PE (1) PE20080670A1 (enExample)
PL (1) PL2074122T3 (enExample)
PT (1) PT2074122E (enExample)
RS (2) RS51927B (enExample)
SI (1) SI2074122T1 (enExample)
TN (1) TN2009000085A1 (enExample)
TW (1) TWI334353B (enExample)
UY (1) UY30588A1 (enExample)
WO (1) WO2008032162A1 (enExample)
ZA (1) ZA200901477B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
PT2139484E (pt) * 2007-04-10 2013-10-31 Exelixis Inc Métodos de tratamento de cancro usando inibidores piridopirimidinona de pi3k-alfa
CA2683820A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022128A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN103764144B (zh) 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
EP3549583A1 (en) 2014-10-10 2019-10-09 Pfizer Inc Synergistic auristatin combinations
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
CN109803968A (zh) * 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
AU2017376766A1 (en) * 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
IL312844A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and compositions for treating cancer
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
AU2024286830A1 (en) 2023-06-08 2025-12-04 Nimbus Wadjet, Inc. Wrn inhibitors
WO2025137599A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
FI971953A7 (fi) 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
SK10772002A3 (sk) 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine and naphthyridine derivatives
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
BR0309581A (pt) 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
PL1713806T3 (pl) 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
CA2555724A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US7767687B2 (en) 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
PT1940839E (pt) * 2005-10-07 2013-10-10 Exelixis Inc Inibidores de piridopirimidinona pi3k alfa
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
CA2663401C (en) 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
BRPI0808772A2 (pt) * 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
CA2683820A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
CA2663401A1 (en) 2008-03-20
BRPI0716749A2 (pt) 2014-02-18
TW200820972A (en) 2008-05-16
NI200900032A (es) 2010-05-14
PL2074122T3 (pl) 2011-10-31
US7696213B2 (en) 2010-04-13
NZ575167A (en) 2010-10-29
MA30709B1 (fr) 2009-09-01
GT200700077A (es) 2009-08-03
CN101573358A (zh) 2009-11-04
US20100137279A1 (en) 2010-06-03
US20080090801A1 (en) 2008-04-17
MY146420A (en) 2012-08-15
HN2007000267A (es) 2011-02-25
CR10662A (es) 2009-04-17
US8273755B2 (en) 2012-09-25
RS51927B (sr) 2012-02-29
BRPI0716749B1 (pt) 2020-10-06
US8633204B2 (en) 2014-01-21
IL197243A0 (en) 2009-12-24
AU2007297212B8 (en) 2011-04-28
NO342357B1 (no) 2018-05-14
WO2008032162A1 (en) 2008-03-20
UY30588A1 (es) 2008-05-02
CU23783B7 (es) 2012-02-15
NO20091141L (no) 2009-03-31
GEP20115306B (enExample) 2011-10-10
KR20090040389A (ko) 2009-04-23
DOP2009000039A (es) 2015-12-15
CN101573358B (zh) 2012-05-30
EP2074122A1 (en) 2009-07-01
DK2074122T5 (da) 2014-03-17
TWI334353B (en) 2010-12-11
SI2074122T1 (sl) 2011-10-28
EP2074122B9 (en) 2013-09-11
ZA200901477B (en) 2010-07-28
AP2710A (en) 2013-07-30
ES2366489T9 (es) 2013-12-27
CA2663401C (en) 2011-07-12
RS20090104A (sr) 2010-06-30
EA016388B1 (ru) 2012-04-30
ATE514695T1 (de) 2011-07-15
US20120309775A1 (en) 2012-12-06
MX2009002927A (es) 2009-03-31
KR101099926B1 (ko) 2011-12-28
PT2074122E (pt) 2011-08-24
JP2010503653A (ja) 2010-02-04
IL197243A (en) 2013-07-31
EP2074122B1 (en) 2011-06-29
AU2007297212B2 (en) 2011-04-14
HRP20110621T2 (hr) 2013-12-06
AU2007297212A1 (en) 2008-03-20
ES2366489T3 (es) 2011-10-20
DK2074122T3 (da) 2011-08-15
PE20080670A1 (es) 2008-06-14
CL2007002682A1 (es) 2008-04-04
JP4718637B2 (ja) 2011-07-06
HK1138589A1 (en) 2010-08-27
WO2008032162A8 (en) 2009-03-26
MEP8009A (en) 2011-12-20
AR062785A1 (es) 2008-12-03
TN2009000085A1 (fr) 2010-08-19
AP2009004790A0 (en) 2009-04-30
EA200970207A1 (ru) 2009-08-28
HRP20110621T1 (hr) 2011-09-30
CY1111911T1 (el) 2015-11-04
CU20090040A7 (es) 2011-07-11

Similar Documents

Publication Publication Date Title
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
UY32420A (es) Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
BR112013021638A2 (pt) "compostos inibidores de trk, seu uso e composições que os compreendem"
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
DOP2014000303A (es) 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
ECSP099565A (es) Compuesto de 2-amino pirimidina
BR112012014058A8 (pt) Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
DOP2010000155A (es) Derivados de pirazol como inhibidores de 5-lo
UY31161A1 (es) Usos de derivados de cinolina en el tratamiento de la esquizofrenia
UY32412A (es) DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIMIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
TH151329A (th) ไพริมิดิโนนเป็นสารยับยั้ง pi3k
CU23957B1 (es) Derivados de tiazolidin-2,4-diona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2686 DE 28-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.